A practical survey of fertility-preservation treatments in the startup phase in Japan.
cancer survivor
fertility preservation
oncofertility
oocyte cryopreservation
ovarian tissue cryopreservation
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
revised:
26
01
2022
received:
25
11
2021
accepted:
09
02
2022
pubmed:
12
3
2022
medline:
30
4
2022
entrez:
11
3
2022
Statut:
ppublish
Résumé
The actual status of fertility preservation treatments in the startup phase in Japan was investigated as a basis for discussing future directions. This study was conducted as "Research project to promote support of children and parenting 2016" which was supported by Ministry of Health in Japan with the approval of the institutional review board at St. Marianna University. Subjects of the survey were facilities registered with the Japan Society of Obstetrics and Gynecology as fertility preservation facilities, and facilities belonging to the Japan Association of Private Assisted Reproductive Technology Clinics and Laboratories. We provided questionnaires to survey both the medical care system and cases for which fertility preservation was implemented between 2006 and 2016. Responses were obtained from 68 facilities (of the 64, 59 [92.2%] responded to the questionnaire and 9 clinics cooperated). Many facilities limited the cryopreservation of oocytes and ovaries to patients 40-41 years old and the use of eggs to patients 44-45 years old. In the patient survey, 812 cases of oocyte cryopreservation and 201 cases of ovarian tissue cryopreservation were performed during study period. Breast cancer was the most indicated disease, with oocyte cryopreservation in the late 30s and ovarian tissue cryopreservation in the early 30s. Very few babies were born from fertility preservation, and no live birth cases of ovarian tissue cryopreservation were identified. Even from the early days, fertility preservation was implemented according to certain standards in Japan, but was characterized by a large variety of facilities.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1061-1075Subventions
Organisme : Research project to promote support of children and parenting 2016
Informations de copyright
© 2022 Japan Society of Obstetrics and Gynecology.
Références
von Wolff M, Andersen CY, Woodruff TK, Nawroth F. FertiPROTEKT, Oncofertility consortium and the Danish fertility-preservation networks - what can we learn from their experiences? Clin Med Insights Reprod Health. 2019;13:1179558119845865.
Takae S, Lee JR, Mahajan N, et al. Fertility preservation for child and adolescent cancer patients in Asian countries. Front Endocrinol. 2019;10:655.
Preservation EGGoFF, Anderson RA, Amant F, et al. ESHRE guideline: female fertility preservation. Hum Reprod Open. 2020;2020(4):hoaa052.
Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clinical Oncol. 2018;36(19):1994-2001.
Lambertini M, Peccatori FA, Demeestere I, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2020;31(12):1664-78.
Schüring AN, Fehm T, Behringer K, et al. Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: indications for fertility preservation. Arch Gynecol Obstet. 2018;297(1):241-55.
von Wolff M, Germeyer A, Liebenthron J, Korell M, Nawroth F. Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part II: fertility preservation techniques. Arch Gynecol Obstet. 2018;297(1):257-67.
Suzuki N. Clinical practice guidelines for fertility preservation in pediatric, adolescent, and young adults with cancer. Int J Clin Oncol. 2019;24(1):20-7.
Europe EWGoOCi, Shenfield F, de Mouzon J, et al. Oocyte and ovarian tissue cryopreservation in European countries: statutory background, practice, storage and use. Hum Reprod Open. 2017;2017(1):hox003.
Sanada Y, Harada M, Kunitomi C, et al. A Japanese nationwide survey on the cryopreservation of embryos, oocytes and ovarian tissue for cancer patients. J Obstet Gynaecol Res. 2019;45(10):2021-8.
Okamoto S, Fujii N, Yoshioka N, et al. Nationwide survey of fertility preservation in patients with hematological malignancies in Japan. Int J Clin Oncol. 2021;26(2):438-42.
Salama M, Isachenko E, Ludwig S, et al. A successful multidisciplinary approach for treatment and for preserving the reproductive potential in a rare case of acute lymphocytic leukemia during pregnancy. Gynecol Endocrinol. 2019;35(2):115-8.
Salama M, Anazodo A, Woodruff TK. Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach. Ann Oncol. 2019;30(11):1760-75.
Stern C, Agresta F. Setting up a fertility preservation programme. Best Pract Res Clin Obstet Gynaecol. 2019;55:67-78.
Practice Committee of the American Society for reproductive medicine. Electronic address aao. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2019;112(6):1022-33.
Takae S, Furuta S, Keino D, et al. Surgical management of unilateral oophorectomy for ovarian tissue cryopreservation in high-risk children and adolescents with varied backgrounds. Pediatr Surg Int. 2021;37(8):1021-9.
Anazodo A, Laws P, Logan S, et al. How can we improve oncofertility care for patients? A systematic scoping review of current international practice and models of care. Hum Reprod Update. 2019;25(2):159-79.
Frederick NN, Fine E, Michaud A, Recklitis CJ, Bober SL. Pediatric hematology and oncology fellow education in sexual and reproductive health: a survey of fellowship program directors in the United States. Pediatr Blood Cancer. 2020;67(5):e28245.
Furui T, Takenaka M, Makino H, Terazawa K, Yamamoto A, Morishige KI. An evaluation of the Gifu model in a trial for a new regional oncofertility network in Japan, focusing on its necessity and effects. Reprod Med Biol. 2016;15(2):107-13.
Yasmin E, Balachandren N, Davies MC, et al. Fertility preservation for medical reasons in girls and women: British fertility society policy and practice guideline. Hum Fertil (Camb). 2018;21(1):3-26.
Mulder RL, Font-Gonzalez A, Hudson MM, et al. Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2021;22(2):e45-56.
Dolmans MM, Lambertini M, Macklon KT, et al. EUropean REcommendations for female FERtility preservation (EU-REFER): a joint collaboration between oncologists and fertility specialists. Crit Rev Oncol Hematol. 2019;138:233-40.
Lotz L, Dittrich R, Hoffmann I, Beckmann MW. Ovarian tissue transplantation: experience from Germany and worldwide efficacy. Clin Med Insights Reprod Health. 2019;13:1179558119867357.
Dolmans MM, Luyckx V, Donnez J, Andersen CY, Greve T. Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue. Fertil Steril. 2013;99(6):1514-22.
Shapira M, Raanani H, Barshack I, et al. First delivery in a leukemia survivor after transplantation of cryopreserved ovarian tissue, evaluated for leukemia cells contamination. Fertil Steril. 2018;109(1):48-53.
Kawwass JF, Shandley LM, Boulet SL, Hipp HS. Oncologic oocyte cryopreservation: national comparison of fertility preservation between women with and without cancer. J Assist Reprod Genet. 2020;37(4):883-90.
Kristensen SG, Pors SE, Poulsen LC, Andersen ST, Wakimoto Y, Yding AC. Time from referral to ovarian tissue cryopreservation in a cohort of Danish women. Acta Obstet Gynecol Scand. 2019;98(5):616-24.
Poirot C, Brugieres L, Yakouben K, et al. Ovarian tissue cryopreservation for fertility preservation in 418 girls and adolescents up to 15 years of age facing highly gonadotoxic treatment. Twenty years of experience at a single center. Acta Obstet Gynecol Scand. 2019;98(5):630-7.
Jadoul P, Guilmain A, Squifflet J, et al. Efficacy of ovarian tissue cryopreservation for fertility preservation: lessons learned from 545 cases. Hum Reprod. 2017;32(5):1046-54.
Tatsumi T, Jwa SC, Kuwahara A, Irahara M, Kubota T, Saito H. No increased risk of major congenital anomalies or adverse pregnancy or neonatal outcomes following letrozole use in assisted reproductive technology. Hum Reprod. 2017;32(1):125-32.
Sonmezer M, Turkcuoglu I, Coskun U, Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril. 2011;95(6):2125.e9-e11.
Wallace WH, Smith AG, Kelsey TW, Edgar AE, Anderson RA. Fertility preservation for girls and young women with cancer: population-based validation of criteria for ovarian tissue cryopreservation. Lancet Oncol. 2014;15(10):1129-36.
Beckmann MW, Lotz L, Toth B, et al. Concept paper on the technique of cryopreservation, removal and transplantation of ovarian tissue for fertility preservation. Geburtshilfe Frauenheilkd. 2019;79(1):53-62.
Beckmann MW, Dittrich R, Lotz L, et al. Fertility protection: complications of surgery and results of removal and transplantation of ovarian tissue. Reprod Biomed Online. 2018;36(2):188-96.
Rowell EE, Corkum KS, Lautz TB, et al. Laparoscopic unilateral oophorectomy for ovarian tissue cryopreservation in children. J Pediatr Surg. 2019;54(3):543-9.
Beckmann MW, Dittrich R, Lotz L, et al. Operative techniques and complications of extraction and transplantation of ovarian tissue: the Erlangen experience. Arch Gynecol Obstet. 2017;295(4):1033-9.
Kedem A, Yerushalmi GM, Brengauz M, et al. Outcome of immature oocytes collection of 119 cancer patients during ovarian tissue harvesting for fertility preservation. J Assist Reprod Genet. 2018;35(5):851-6.
Fasano G, Dechene J, Antonacci R, et al. Outcomes of immature oocytes collected from ovarian tissue for cryopreservation in adult and prepubertal patients. Reprod Biomed Online. 2017;34(6):575-582.
Segers I, Bardhi E, Mateizel I, et al. Live births following fertility preservation using in-vitro maturation of ovarian tissue oocytes. Hum Reprod. 2020;35(9):2026-36.
Macklon KT. Prevalence of deaths in a cohort of girls and women with cryopreserved ovarian tissue. Acta Obstet Gynecol Scand. 2019;98(5):625-9.
Hoekman EJ, Louwe LA, Rooijers M, et al. Ovarian tissue cryopreservation: low usage rates and high live-birth rate after transplantation. Acta Obstet Gynecol Scand. 2020;99(2):213-21.
Rashedi AS, de Roo SF, Ataman LM, et al. Survey of fertility preservation options available to patients with cancer around the globe. JCO Glob Oncol. 2020;6:JGO.2016.008144.